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Abstract
Background Left ventricular dysfunction and the develop-
ment of heart failure is a frequent and serious com-
plication of myocardial infarction. Recent animal exper-
imental studies suggested that metformin treatment
reduces myocardial injury and preserves cardiac func-
tion in non-diabetic rats after experimental myocardial
infarction. We will study the efficacy of metformin with
the aim to preserve left ventricular ejection fraction in
non-diabetic patients presenting with ST elevation myo-
cardial infarction (STEMI).
Methods The Glycometabolic Intervention as adjunct to
Primary percutaneous intervention in ST elevation myocar-
dial infarction (GIPS)-III trial is a prospective, single center,
double blind, randomized, placebo-controlled trial. Three-
hundred-and-fifty patients, without diabetes, requiring pri-
mary percutaneous coronary intervention (PCI) for STEMI
will be randomized to metformin 500 mg twice daily or
placebo treatment and will undergo magnetic resonance
imaging (MRI) after 4 months. Major exclusion criteria
were prior myocardial infarction and severe renal dysfunc-
tion. The primary efficacy parameter is left ventricular ejec-
tion fraction 4 months after randomization. Secondary and
tertiary efficacy parameters include major adverse cardiac
events, new onset diabetes and glycometabolic parame-
ters, and echocardiographic diastolic function. Safety
parameters include renal function deterioration and lactic
acidosis.
Conclusions The GIPS-III trial will evaluate the efficacy of
metformin treatment to preserve left ventricular ejection
fraction in STEMI patients without diabetes.
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Background
Primary percutaneous coronary intervention (PCI) reduces
early mortality and improves late clinical outcome in
patients with acute myocardial infarction (MI). Large MI
size and adverse left ventricular remodeling may cause post
infarct deterioration of left ventricular function and devel-
opment of overt heart failure.
Metformin, a biguanide oral antihyperglycemic agent used
widely for the treatment of patients with type 2 diabetes
mellitus, enhances glucose control through increased glucose
utilization and decreased endogenous glucose release [1, 2].
Several studies in patients with diabetes demonstrated that
metformin is associated with improved outcome and consid-
ered to be safe (Table 1) [3–9]. Furthermore, in patients at high
risk of developing diabetes, metformin reduced the incidence
of diabetes [10, 11].
Several preclinical studies in non-diabetic animals reported
that metformin may confer cardioprotection by limiting MI
size and preventing adverse remodeling. Recently, our group
demonstrated that metformin reduces infarct size by 22 % in
an experimental non-diabetic rat model of MI, resulting in a
relative improvement in left ventricular ejection fraction
(LVEF) of 52 % compared to placebo (Fig. 1) [12]. These
effects were independent from glycemic control, as these were
non-diabetic normoglycemic rats [12]. Other groups con-
firmed these results in murine and canine models, demonstrat-
ing metformin treatment compared to placebo reducedMI size
between 22 % to 58 % [13–17], and resulted in a relative
improvement in LVEF between 31 and 52 % [13, 14].
Current medical strategies are predominantly aimed at
establishing reperfusion and secondary prevention including
prevention of thrombo-embolism and inhibition of the
renin-angiotensin system. Reducing infarct size and positive
cardiac remodeling by metformin therapy provides a poten-
tial novel strategy to preserve functional myocardium and
thereby improve prognosis.
Mechanism of action and potential benefit
Effects of metformin include decreased hyperglycemia,
hypoinsulinemia, higher peripheral muscle glucose uptake,
decreased hepatic glyconeogenesis, reduced hypercoagula-
bility, improvement of the lipid profile, nitric oxide mediated
vasodilatation, and additional cardioprotective effects [1].
Reported cardioprotective effects of metformin include atten-
uation of myocardial infarct size and improved left ventricular
function. The exact mechanisms of action that explain these
numerous effects of metformin remain to be elucidated. Espe-
cially our understanding of the cardioprotective effects of
metformin, beyond glucose lowering, is incomplete [18]. Sev-
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metformin induced cardioprotection, these are displayed in
detail in Fig. 2 [12–33].
Collectively, the metformin induced changes in myocardial
gene and energy program, especially the activation of AMPK,
are associated with decreased infarct size, prevention of
adverse remodeling, and result ultimately in improved cardiac
function.
Study design
The GIPS-III trial is a single center, prospective, double-blind,
randomized, placebo-controlled trial, designed to evaluate the
efficacy of a 4 month metformin treatment on preservation of
LVEF in non-diabetic STEMI patients requiring primary PCI
treatment. A total of 350 non-diabetic STEMI patients will be
included in the GIPS-III trial.
Eligibility
In- and exclusion criteria are listed in Table 2. In brief,
subjects presenting with an acute STEMI treated with pri-
mary PCI, including the implantation of at least 1 stent with
a diameter of at least 3.0 mm are considered for this trial.
Verbal followed by written informed consent will be required
from each patient.
Treatment
All patients will receive standard medical treatment for a
STEMI according to European practice guidelines [34].
The flow chart of the GIPS-III trial is shown in Fig. 3.
During the primary PCI procedure witnessed verbal informed
consent will be obtained by the interventional cardiologist and
additional blood samples will be drawn for storage. As soon as
possible, but no more than 3 h after successful PCI, patients
will be randomly assigned to a 4 month treatment with white
film-coated tablets containing metformin hydrochloride
500 mg or visually matching placebo, administered twice
daily. Secondary prevention will according to ESC guidelines
include aspirin, thienopyridines, statins, angiotensin convert-
ing enzyme (ACE) inhibitors, and beta-receptor blockers,
when indicated and tolerated [34, 35].
Subjects are scheduled for return visits at 2 weeks,
2 months, 4 months, and 12 months after hospital discharge.
During every visit examination, assessment of clinical
events and 12-lead electrocardiography are performed. Dur-
ing the 4 month visit the amount of study drug received,
dispensed, and consumed will be recorded.
Study drug treatment will be discontinued in the follow-
ing situations: 1) when subject withdraw consent, 2) in case
of pregnancy, 3) when subjects develop severe renal dys-
function (defined as creatinin >177 μmol/L, or an estimated
GFR <30 ml/min*1.73 m2), or 4) when subjects develop a
condition which, in the investigator’s judgment, precludes
further therapy. Discontinuation will have no consequence
for the regular patient care. Since metformin therapy used as
a single antihyperglycemic drug is not associated with hy-
poglycemia and due to the blinded nature of this trial, there
will be no dose modifications of the study medication.
Study efficacy parameters
The primary efficacy parameter of the GIPS-III trial is LVEF
measured by cardiac MRI 4 months after randomization,
based on an intention-to-treat analysis. LVEF, is an impor-
tant predictor of prognosis after MI [36, 37].
A per-protocol analysis, excluding patients diagnosed
with new onset diabetes and treated with oral antihypergly-
ceemic agents or insulin prior to cardiac MRI, will be
performed as a secondary efficacy parameter. Other second-
ary efficacy parameters include major cardiac adverse
events (MACE; death, recurrent MI, target lesion revascu-
larization), stroke, non-elective hospitalizations for chest
pain or heart failure, all recurrent coronary interventions,
and internal cardiac defibrillator implantations. Mortality
will be divided into cardiac and non-cardiac. Cardiac death
will be divided into three categories: heart failure, sudden
death and other. A cardiologist will confirm deaths from
cardiovascular causes by examining medical records
obtained from hospitals and attending physicians or from
the attending general practitioner if the patient died at home.
Further, echocardiographic parameters of diastolic function,
incidence of new onset diabetes, additional parameters
Fig. 1 metformin resulted in a relative improvement in left ventricular
ejection fraction of 52 % compared to placebo. MI: myocardial infarc-
tion; *P<0.05 vs. sham group; # P<0.05 vs. placebo group. Adapted
with permission from: Fig. 2 from Meimei Yin, Iwan CC van der
Horst, Joost P van Melle, Cheng Qian, Wiek H van Gilst, Herman
HW Silljé, and Rudolf A de Boer. Metformin improves cardiac func-
tion in a nondiabetic rat model of post-MI heart failure. Am J Physiol
Heart Circ Physiol August 2011 301:(2) H459–H468
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measured by MRI, skin autofluorescence, electrocardio-
graphic parameters, and blood sample analyses, will be used
as tertiary efficacy endpoints.
Magnetic resonance imaging
Cardiovascular MRI is considered the most accurate mea-
sure to date for evaluation of LVEF, the extent of myocardial
infarct size, and several other functional parameters [36].
The diagnostic accuracy of MRI for evaluation of LVEF
allows a sample size reduction compared to other imaging
modalities. Patients are studied with a 3.0 Tesla clinical
scanner (3 T Achieva, Philips, Best, The Netherlands) at
the NeuroImaging Center (NIC, University of Groningen,
Groningen, The Netherlands) (Appendix C) using a phased
array cardiac receiver coil. Electrocardiogram-gated cine
steady-state, free precession magnetic resonance images
acquired during repeated breath holds in the standard long-
Fig. 2 visualization of the proposed cardioprotective mechanism of
action of metformin in the human heart after myocardial infarction,
resulting in improved systolic and diastolic function. In experimental
models metformin has been consistently associated with enhanced
phosphorylation of AMP activated protein kinase (AMPK) [12–24].
In the myocardium, characterized by high energy demands and low
energy reserves, AMPK plays a pivotal role in maintaining metabolic
homeostasis [18–21]. Metformin-induced AMPK phosphorylation
may be mediated by inhibition of complex 1 of the respiratory chain,
by upstream activation of the tumor suppressor gene liver kinase B1
(LKB1), or by decreased AMP–deaminase activity [21–24]. AMPK
phosphorylation leads to activation of the Reperfusion Injury Salvage
Kinase (RISK) pathway including phospatidylinositol-3-kinase (PI3K)
and Akt pathways [17, 26], upregulation of the tumor suppressor gene
p53 [27], inhibition of mammalian target of rapamycin (mTOR) [19],
and upregulation of endothelial nitric oxide synthase (eNOS) [1, 13].
Activation of the RISK pathway and eNOS improves mitochondrial
function and inhibits opening of the mitochondrial permeability tran-
sition pore (mPTP) [26]. The mPTP is a major mediator of myocardial
reperfusion injury. Opening of the mPTP results in ATP depletion and
cell death [25, 26]. Further, prevention of mPTP opening stimulates
mitochondrial respiration, improving ATP availability and cellular
function [25]. Upregulated p53 and inhibited mTOR, partly RISK
pathway mediated, are associated with decreased cellular vulnerability
by preventing post-mitotic cell death and improved resilience to ische-
mia related injury [19, 27]. Metformin mediated eNOS production,
next to increasing nitric oxide production, enhances sodium pump
activity causing decreased intracellular calcium levels [1]. In infarcted
tissue, this may attenuate microvascular obstruction and thereby pre-
vent mPTP mediated cell death [28]. In functional myocardium, opti-
mized calcium handling results in improved contractility and relaxation
[1]. Further, independent of AMPK, metformin inhibits transforming
growth factor (TGF)-β1 myocardial expression, decreasing collagen
synthesis and preventing fibrosis [29]. Metformin may also attenuate
cardiac fibrosis by directly inhibiting advanced glycation endproduct
(AGE) formation [30]. Also, metformin is associated with a decrease in
dipeptidyl peptidase-4 activity and an increase in circulating levels of
glucagon-like peptide 1 [31]. In a porcine model of ischemia and
reperfusion injury, stimulation with a analogue (exenatide) resulted in
a reduction of infarct size [32]. Another target of metformin may be the
increase of glucose utilisation of the heart. The adult heart mainly relies
on fatty acids utilisation, and switches back to glucose when damaged.
However, metabolic flexibility of the failing heart is limited, and
facilitation of glucose utilisation by metformin via increase of glucose
transporters (GLUT-1 and GLUT-4) may explain its salutary effects on
the cardiac function [12, 33]
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axis views (4-, 3-, and 2-chamber view) and contiguous short-
axis slices covering the entire left ventricle are used to assess
global and regional ventricular function and to calculate LVEF
(primary endpoint). Using identical slice locations, late
contrast-enhanced (LCE) images are acquired 10 min after
intravenous administration of a gadolinium-based contrast
agent (Dotarem, Gorinchem, the Netherlands; 0.2 mmol/kg)
with an inversion-recovery, gradient-echo pulse sequence to
identify the location and extent of MI. The inversion time will
be set to null the signal of viable myocardium for every
Table 2 In- and exclusion cri-






Inclusion criteria Exclusion criteria
• The diagnosis acute MI defined by chest pain suggestive
for myocardial ischemia for at least 30 min, the time
from onset of the symptoms less than 12 h before hospital
admission, and an ECG recording with ST- segment
elevation of more than 0.1 mV in 2 or more leads
• Prior MI
• Diabetes
• Creatinin >177 μmol/L measured pre-PCI
• Need for coronary artery bypass grafting
• Rescue PCI after thrombolytic therapy
• Successful primary PCI <12 h from onset of symptoms • When subjects develop a condition which,
in the investigator’s judgment, precludes study therapy
• Verbal followed by written informed consent • Inability to provide informed consent
• At least one stent sized ≥3.0 mm • Younger than 18 years
• Eligible for cardiac MRI-scan: • Contra-indication to metformin
- Body Mass Index <40 kg/m2 • an estimated life-expectancy of less than 6 months
- no ferromagnetic metal objects in the body
- no claustrophobia





left ventricular ejection fraction;
MRI magnetic resonance
imaging; OGTT oral glucose
tolerance testing
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individual patient. All MRI data are sent to independent
cardiologists, blinded for randomization status, for quality
control and blinded analysis (Appendix D).
The MRI data are analyzed using a dedicated software
package. On the stack of short-axis cines, the endocardial
and epicardial borders are outlined in end systolic and end
diastolic images. Left ventricular end diastolic volume
(LVEDV) and left ventricular end systolic volume
(LVESV) are calculated using the summation of slice meth-
od multiplied by slice distance. LVEF is calculated as
LVEF0100 %×(LVEDV-LVESV)/LVEDV. Summation of
the volumes per slice of areas of hyperenhancement is out-
lined, allowing to calculate total infarct size.
Echocardiography
Two-dimensional echocardiography with a phased array
electronic ultrasound will be performed 0–2 days after ran-
domization and 4 months after randomization. Tissue Dopp-
ler (TD) imaging of the early mitral valve flow velocity/
early TD lengthening velocity (E/E’), the ratio of the early
(E) to late (A) mitral valve flow velocity, the deceleration
time, the left atrial volume index (LAVI), and the difference
between the duration of reverse pulmonary vein atrial
systole flow (Ard) and mitral valve atrial wave flow
(Ad) will be used to determine and classify diastolic
function.
Skin autofluorescence
Tissue AGE accumulation will be assessed using a validated
skin autofluorescence (AF) reader (advanced glycation end-
products reader; patent PCT/NL99/00607; DiagnOptics BV,
Groningen, The Netherlands) [38]. In short, a skin surface of
approximately 2 cm2 is illuminated by the AGE-reader with
an peak excitation of ~370 nm. The reflected light from the
skin is measured with a spectrometer in the 420–600 nm
range, using 200 μm glass fibers. The value of skin AF is
calculated as the ratio of the light intensity in the 420–
600 nm wavelength range and the light intensity in the
300–420 nm wavelength range. Skin AF will be measured
during hospitalization, and 4 months after randomization.
Electrocardiography
A standard 12-lead electrocardiogram is acquired at the time
of presentation, after the PCI procedure, before hospital
discharge, and at each outpatient clinic visit. Mean time
interval between pre and post intervention will be registered.
Pre-intervention ECG will be analyzed on the presence of
ST-deviation. The post-intervention ECGs will be used to
score persistent ST-deviation and ST-segment resolution,
and the incidence and location of new Q-waves.
Laboratory analysis
During hospitalization, blood will be sampled at baseline
and at 3, 6, 9, 12, and 24 h after PCI to monitor values of
cardiac enzymes and high sensitive troponin [39]. Less
frequently during hospitalization and at every visit to the
outpatient clinic hemoglobin, platelets, glucose, creatinin
and liver enzymes, total cholesterol, high-density and low-
density lipoprotein, and N-terminal pro B-type natriuretic
peptide will be determined.
Furthermore, during PCI, 24 h after PCI, and at every
visit to the outpatient clinic, blood samples for additional
analyses will be collected [40]. These analyses will include,
but are not limited to, glycometabolic determinants, bio-
markers, and other markers of disease severity or relevant
to the disease [41, 42].
Diabetes and prediabetes
For assessment of diabetes and prediabetes, an oral glucose
tolerance test (OGTT) will be performed during initial hos-
pitalization and after study medication is stopped according
to protocol and after primary endpoint analysis, next to the
level of glycated hemoglobin (HbA1c) [40]. Diabetes and
prediabetes will be diagnosed according to current guide-
lines [43]. Whenever new onset diabetes is diagnosed,
patients will be treated by an endocrinologist according to
current guidelines, additional to study treatment. Metformin
can be started on top of study medication in a dose of
500 mg three times per day, to prevent exceeding maximal
metformin dose. Patients who next to standard care and life
style interventions need oral antihyperglycemic agents or
insulin for glucose control prior to primary endpoint analy-
sis will be excluded from the per protocol analysis.
Statistical considerations
Sample size
The sample size is calculated for the difference in the
primary efficacy parameter (LVEF measured by MRI at
4 months) between the intervention group and the placebo
group. With 80 % power to detect a 3 % difference in LVEF
between active treatment and control (assuming a 2-sided α
of 0.05 and an SD of 9 % for the change in LVEF) 141
patients are needed in each study group. A 3 % difference in
LVEF is considered to be a clinically relevant outcome [37].
Based on local experience from previous studies, we assume
that MRI analysis will be unavailable in up to 24 % of
patients (due to study withdrawal, development of contra-
indications e.g. ICD, claustrophobia, etc.) [44, 45]. To main-
tain 80 % power, an increase to a total of 350 patients is
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required. However, if actual study completion rates differ
from predicted rates, recruitment will be extended in order
to achieve 282 patients with primary endpoint analysis. The
maximal number of patients to which the inclusion can be
extended in this trial will be limited to 380.
Statistical analyses of primary and secondary efficacy
parameters
The primary efficacy parameter of the study is measured
4 months after randomization. For the analysis of binary
endpoints, treatment comparisons will be performed using
Fisher exact probability test or Chi-square analysis. For
continuous outcomes, independent samples t test or a
Mann–Whitney U test will be used, as appropriate. For
clinical outcomes such as the incidence of major adverse
cardiac events, Cox regression will be used to evaluate the
association between the intervention and the endpoints.
Kaplan-Meier curves displaying the pattern of events over
the 4-month and long-term follow-up period will be drawn.
Study organization and monitoring
The GIPS-III trial is performed by the GIPS-III investigators
(Appendix A), supervised by a steering committee (Appendix
B). The steering committee is responsible for design and
conduct of the study. Periodic assessments of safety are being
performed by an independent data and safety monitoring
board (DSMB) (Appendix E). Study endpoints will be
assessed by an independent endpoint adjudication committee
(EAC) (Appendix F). Data monitoring and data management
will be performed by the independent Trial Coordination
Center (Appendix G). For valorization purposes a users’ com-
mittee will be installed (Appendix H). The trial registration
number is NCT01217307 (www.clinicaltrials.gov).
Discussion
The GIPS-III trial will be the first randomized, double-blind,
placebo-controlled trial to study the efficacy of metformin on
preservation of LVEF in non-diabetic STEMI patients. This
trial will provide valuable information on whether metformin
can preserve LVEF and reduce myocardial infarct size after
STEMI and might extend its clinical efficacy beyond patients
with diabetes. LVEF was chosen as the primary efficacy
parameter as this provides an important reflection of the
functional consequences of post infarction cardiac remodeling
and is probably more important than anatomical area at risk.
A unique aspect of the GIPS-III trial is that we evaluate
non-glycemic effects of metformin in a non-diabetic popu-
lation. In the current trial we excluded patients with a history
of diabetes. Diabetes diagnosed after randomization will be
regarded as “new onset diabetes” and will be treated by an
endocrinologist which could include metformin treatment in
addition to study drug treatment. According to the intention-
to-treat principle, these patients will be included in the
primary efficacy parameter analysis. For the secondary per
protocol analysis these patients will be excluded.
We excluded patients with documented myocardial infarc-
tion from the GIPS-III trial to avoid inclusion of subjects with
reduced LVEF at baseline, which might complicate the inter-
pretation of our data. We also included only subjects with a
STEMI based on a vessel requiring a stent diameter of at least
3 mm as an indicator of a relatively large area at risk which
might potentially result in a clearly reduced LVEF. Although
the exact mechanism of metformin remains to be elucidated,
we start study treatment immediate (within 3 h) after PCI to
have the largest possible window of opportunity. Our primary
efficacy parameter will be evaluated 4 months after primary
PCI. After 4 months would healing should be completed and
partial or complete remodeling should have occurred [46].
Several prospective trials in patients with diabetes have
reported a favorable outcome associated with metformin.
Several retrospective analyses have demonstrated additional
effects on cardiovascular endpoints. No prospective trial has
yet shown the effects of metformin on myocardial infarct size
and cardiac function. The effects and pathways allegedly
responsible for the metformin-induced cardioprotective
effects have not yet been studied in the human setting. More-
over, the exact contribution and efficacy of the supposed
metformin mediated mechanisms to improved systolic and
diastolic myocardial function is unclear. However, retrospec-
tive data consistently showed that metformin therapy was
associated with improved outcome in diabetic patients (Ta-
ble 1). In non-diabetic preclinical studies a consistent reduc-
tion in myocardial infarct size and improvement in left
ventricular function has been reported [12–17]. Therefore,
the GIPS-III trial may be regarded as a proof-of-principle trial
focused on the cardioprotective effects of metformin. Collec-
tively, we hypothesize that the metformin induced changes in
myocardial gene and energy program, especially the activa-
tion of AMPK, will be associated with decreased infarct size,
prevention of adverse remodeling, and may ultimately result
in improved systolic function (Fig. 2). Diastolic function
might also be improved by attenuating fibrosis and improving
myocardial relaxation (Fig. 2). Extensive secondary analyses
will allow to study the mechanisms involved with metformin
use in a non diabetic population.
Current status
The GIPS-III trial has been approved by the local institu-
tional review board, national regulatory agencies, and is
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being carried out according the Declaration of Helsinki
(Seoul 2008). GIPS-III has enrolled its first patient in Jan-
uary 2011. As of August 1st, 2012, 266 patients have been
randomized. Completion of the inclusion is anticipated in
January 2013. Primary endpoint analysis of the final ran-
domized patient is expected in April 2013.
Conclusion
The GIPS-III trial is a single center, prospective, double-
blind, randomized, placebo-controlled trial to determine
whether a 4 month metformin treatment can improve LVEF
in 350 non-diabetic patients presenting with STEMI requir-
ing primary PCI treatment.
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